Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer


( Last Updated : November 24, 2022)
Project Status:
Pending
Therapeutic Area:
Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer
Project Line:
Reimbursement Review
Project Sub Line:
Provisional Funding Algorithm
Project Number:
PH0018-000

Details


Review Type: Panel

Provisional Funding Algorithm

Stakeholder Input Deadline:

December 8, 2022

Draft Report Posted (Target):

January 19, 2023

Stakeholder Feedback Deadline:

January 26, 2023

Final Report Posted (Target):

February 28, 2023

Call for feedback
Call for feedback:
Feedback Due By
Feedback Due By:
Consultation document
Consultation document: Proposed Scope
Product Line
Product Line: Reimbursement Review
Project Number
Project Number: PH0018-000